^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mRNA-4359

    i
    Associations
    News

    Trials

    Company:
    Moderna
    Drug class:
    PD-L1 inhibitor, Immunostimulant, T-cell stimulant, IDO inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (NCT05533697)
    Phase 1/2
    ModernaTX, Inc.
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    08/18/2022
    Primary completion :
    12/08/2027
    Completion :
    12/08/2027
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • mRNA-4359